

# Update on GSK and BARDA \$200 Million Antibiotic Collaboration

*GSK and BARDA provide unique insights into stimulating new antibiotic research through PPP's at SMI's 16th annual conference on Superbugs & Superdrugs*

LONDON, LONDON, UNITED KINGDOM, February 4, 2014 /EINPresswire.com/ -- SMI's Superbugs & Superdrugs conference series has become a focal point for everyone working in the market for infectious diseases. Attending provides a unique forum to engage with KOL's and leading industry experts active in the field. With now just 4 weeks to go until the 16th annual event, places are now strictly limited. For those who are interested in attending you can still book online at [www.superbugssuperdrugs.com](http://www.superbugssuperdrugs.com)



When the U.S. government signed an antibiotics development deal worth up to \$200 million with GlaxoSmithKline to tackle the threats of drug resistance, the collaboration became the first of its kind.

“

There is a paradigm shift in the way Pharma companies are tackling antimicrobial research. The funding of studies and the stance of the regulatory agencies are changing...”

*Sanofi, R&D TSU Infectious Diseases*

Following on from this, Superdrugs & Superdrugs 2014 will provide unique insights from both GSK and BARDA.

Attendees will hear James Anderson, European Partnerships Director from GSK, address the benefits of stimulating antibiotic research through public private partnerships, followed by a keynote address by BARDA Branch Chief, Joseph Larsen. Highlights from the presentation entitled: Working with BARDA, will include,

Overview of BARDA,  
The strategic way of solving critical health issues  
Current research projects with BARDA

BARDA's support in new broad spectrum antibiotic research

[Click here](#) to view conference agenda and full speaker line-up

Delegates will also be able to join the debate and pose questions to both GSK and BARDA, who will then lead a panel discussion alongside The European Commission, EFPIA and TranScrip Partners on: Considering Different Sources of Funding Antibiotic R&D.

A snap shot of attendees who have already confirmed attendance include:

Anacor Pharmaceuticals, Astellas Pharma Europe, Basilea Pharmaceutica Ltd  
Bristol NHS, DSTL Chemical & Biological Sciences, F Hoffmann -La Roche, Ferrer International, Grifols America, Idenix Laboratories, Johnson & Johnson, MedImmune, Melinta Therapeutics, MHRA, NDA Group, Nosopharm, Office for Health Economics, Phico Therapeutics, Procarta Biosystems, Sanofi-Aventis, The Wellcome Trust, Tiber Creek Partners, University of North Texas Health Science Centre  
UNTHSC, PreClinical Services, Valorialia plus many more!

For further details on the conference visit [www.superbugssuperdrugs.com](http://www.superbugssuperdrugs.com)

[Superdrugs & Superbugs](#)

5th - 6th March 2014

Holiday Inn Regents Park, London UK

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/188793813>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.